Maintenance of canine coronary artery patency following thrombolysis with front loaded plus low dose maintenance conjunctive therapy. A comparison of factor Xa versus thrombin inhibition

Cardiovascular Research

Volumn 28, Issue 1, 1994, Pages 78-85

  Lynch, Joseph J ^a   Sitko, Gary R ^a   Mellott, Michael J ^a   Nutt, Elka M ^a   Lehman, E Dale ^a   Friedman, Paul A ^a   Dunwiddie, Christopher T ^a   Vlasuk, George P ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Factor Xa; Hirudin; Thrombolysis; Tick anticoagulant peptide (TAP)

Indexed keywords

ALTEPLASE; BLOOD CLOTTING FACTOR 10A INHIBITOR; LEPIRUDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; DOG; FEMALE; HEART INFARCTION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL;

ANIMAL; COMPARATIVE STUDY; CORONARY DISEASE; DOGS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FACTOR XA; FEMALE; HIRUDIN THERAPY; MALE; PEPTIDES; RECOMBINANT PROTEINS; RECURRENCE; THROMBOLYTIC THERAPY; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR; VASCULAR PATENCY;

EID: 85030304833     PISSN: 00086363     EISSN: None     Source Type: Journal    
DOI: 10.1093/cvr/28.1.78     Document Type: Article

References (43)

1. ISAM Study Group. A prospective trial of Intravenous Streptokinase in Acute Myocardial Infarction (ISAM): mortality, morbidity and infarct size at 21 days. N Engl J Med 1986; 314:1465-71
2. Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico (GISSI). Effectiveness of thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397-102
3. Van de Werf F, Arnold AER. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction. BMJ 1988;297:1374-8
4. Wilcox RG, von der Lippe G, Olsson CG, Jensen G, Skene AM, Hampton JR. Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction: Anglo Scandinavian Study of early thrombolysis (ASSET). Lancet 1988;2:525-30
5. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17,187 cases of suspected, acute myocardial infarction: ISIS-2. Lancet 198S;2:349-60
6. Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM, for the HART Investigators. A comparison between heparin and low dose aspirin as conjunctive therapy with tissue plasminogen activator for acute myocardial infarction. N Engl J Med 1990;323:1433-7
7. Bleich SD, Nichols TC, Schumacher RR, Cooke DH, Tate DA, Teichman SL. Effect of heparin on coronary arterial patency after thrombolysis with tissue plasminogen activator in acute myocardial infarction. Am J Cardiol 1990;66:1412-7
8. de Bono DP, Simoons ML, Tijssen J, et al, for the European Cooperative Study Group. Effect of early intravenous heparin on coronary patency, infarct size and bleeding complications after alteplase thrombolysis: results of a randomized double blind European Cooperative Study Group trial. Br Heart J 1992;67: 122-8
9. Topol EJ, George BS, Kereiakes DJ, et al, and the TAMI Study Group. A randomized controlled trial of intravenous tissue plasminogen activator and early intravenous heparin in acute myocardial infarction. Circulation 1989;79:281-6
10. Gruppo Italiano per lo Studio della Streptochinasi nell’Infarto Miocardico. GISSI-2: a factorial randomized trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet 1990;336:65-71
11. International Study Group. In-hospital mortality and clinical course of 20,891 patients with suspected acute myocardial infarction randomized between tissue plasminogen activator or streptokinase with or without heparin. Lancet 1990;336:71-5
12. Prins MH, Hirsh J. Heparin as an conjunctive treatment after thrombolytic therapy for acute myocardial infarction. Am J Cardiol 1991;67:3-l 1A
13. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomized comparison of strepto kinase versus tissue plasminogen activator versus aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753-70
14. Tiefenbrunn AJ, Sobel BE. Thrombolysis and myocardial infarction. Fibrinolysis 1991;5:1-15
15. Runge MS. Prevention of thrombosis and rethrombosis. New approaches. Circulation 1990;82:655-7
16. Willerson JT, Golino P, McNatt J, Eidt J, Yao S-K, Buja LM. Role of new antiplatelet agents as conjunctive therapies in thrombolysis. Am J Cardiol 1991;67:12-18A
17. Eisenberg PR. Role of new anticoagulants as conjunctive therapy during thrombolysis. Am J Cardiol 1991;67:19-24A
18. Waxman L, Smith DE, Arcuri KE, Vlasuk GP: Tick anticoagulant peptide (TAP) is a novel inhibitor of blood coagulation factor Xa. Science 1990;248:593-6
19. Neeper MP, Waxman L, Smith DE, et al. Characterization of recombinant tick anticoagulant peptide. J Biol Chem 1990;265: 17746-52
20. Jordan SP, Waxman L, Smith DE, Vlasuk GP. Tick anticoagulant peptide: kinetic analysis of the recombinant inhibitor with blood coagulation factor Xa. Biochemistry 1990;29:11095-100
21. Vlasuk GP, Ramjit D, Fujita, et al. Comparison of the in vivo anticoagulant properties of standard heparin and the highly selective factor Xa inhibitors antistasin and tick anticoagulant peptide (rTAP) in a rabbit model of venous thrombosis. Thromb Haemost 1991;65:257-62
22. Schaffer LW, Davidson JT, Vlasuk GP, Siegl PKS. Antithrombotic efficacy of recombinant tick anticoagulant peptide. A potent inhibitor of coagulation factor Xa in a primate model of arterial thrombosis. Circulation 1991;84:1741-8
23. Markwardt F. Development of hirudin as an antithrombotic agent. Semin Thromb Hemost 1989;15:269-82
24. Sitko GR, Ramjit DR, Stabilito II, Lehman D, Lynch JJ. Vlasuk GP. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis. Circulation 1992;85:805-15
25. 2 synthesis: evidence for alternative pathways for coronary thrombosis. J Cardiovasc Pharmacol 1985;7:174-81
26. Jackson CV, Crowe VG, Frank JD, et al. Pharmacological assessment of the antithrombotic activity of the peptide thrombin inhibitor, D-methyl-phenylalanyl-prolyl-arginal (GYKI-14766), in a canine model of coronary artery thrombosis. J Pharmacol Exp Ther 1992;261:546-52
27. Homeister JW, Mickelson JK, Hoff PT, Lucchesi BR. Recombinant hirudin reduces the incidence of thrombotic occlusion in a canine model of coronary vascular injury. Coronary Art Dis 1991;2:237-46
28. Jergens AE, Turrentine MA, Krave KH, Johnson GS. Buccal mucosa bleeding times of healthy dogs and of dogs in various pathologic states, including thrombocytopenia, uremia and von Willebrand’s disease. Am J Vet Res 1987;48:1337-12
29. Lehman ED, Schaefer TF, Przysiecki CT, et ai Large scale purification and characterization of recombinant tick anticoagulant peptide. J Chromatogr 1992;574: 225-35
30. Lehman ED, Joyce JG, Bailey FJ, et al. Expression, purification and characterization of multigram amounts of a recombinant hybrid HV1-HV2 himdin variant expressed in Saccharomvces cerevisiae. Protein Expression Purif 1993;4:247-55
31. Bush LR, Shebuski RJ. In vivo models of arterial thrombosis and thrombolysis. FASEB J 1990;4:3087-98
32. Shebuski RJ, Smith JM, Storer BL, Granett JR, Bugelski PJ. Influence of selective endoperoxide/thromboxane A: receptor antagonism with sulotroban on lysis time and reocclusion rate after tissue plasminogen activator-induced coronary thrombolysis in the dog. J Pharmacol Exp Ther 1988;246:790-6
33. Fitzgerald DJ, FitzGerald GA. Role of thrombin and thromboxane A;in reocclusion following coronary thrombolysis with tissue-type plasminogen activator. Proc Natl Acad Sci USA 1989;86:7585-9
34. Fitzgerald DJ, Wright F, FitzGerald GA. Increased thromboxane biosynthesis during coronary thrombolysis. Evidence that platelet activation and thromboxane A, modulate the response to tissue-type plasminogen activator in vivo. Circ Res 1989;65:83-94
35. Haskel EJ, Prager NA, Sobel BE, Abendschein DR. Relative efficacy of antithrombin compared with antiplatelet agents in accelerating coronary thrombolysis and preventing early reocclusion. Circulation 1991;83:1048-56
36. Yao S-K, Ober JC, Ferguson JJ, et al. Combination of inhibition of thrombin and blockade of thromboxane A, synthetase and receptors enhances thrombolysis and delays reocclusion in canine coronary arteries. Circulation 1992;86:1993-9
37. Prager NA, Torr-Brown SR, Sobel BE. Abendschein DR. Maintenance of patency after thrombolysis in stenotic coronary arteries requires combined inhibition of thrombin and platelets. J Am Coll Cardiol 1993;22:296-301
38. Romson JL, Haack DW, Lucchesi BR. Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of antithrombotic agents. Thromb Res 1980;17:841-53
39. 2-protaglandin endoperoxide receptor activation in vivo. J Clin Invest 1986;77:496-502
40. Heras M, Chesebro JH, Penny WJ, Bailey KR. Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs. Heparin vs recombinant hirudin, a specific thrombin inhibitor. Circulation 1989;79:657-65
41. Heras M, Chesebro JH, Webster MWI, et al. Hirudin, heparin and placebo during deep arterial injury in the pig. The in vivo role of thrombin in platelet-mediated thrombosis. Circulation 1990;82: 1476-84
42. Kelly AB, Marzec UM, Hrupski W, et al. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood 1991;5:1006-12
43. Dunwiddie CT, Smith DE, Nutt EM, Vlasuk GP. Anticoagulant effects of the selective factor Xa inhibitors tick anticoagulant peptide and antistasin in the APTT assay are determined by the relative rate of prothrombinase inhibition. Thromb Res 1991:64: 787-94